Go Pro

AnaptysBio (ANAB) 10K Form and Latest SEC Filings 2026

AnaptysBio logo
$48.53 -0.10 (-0.21%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$48.58 +0.05 (+0.09%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest AnaptysBio SEC Filings & Recent Activity

AnaptysBio (NASDAQ:ANAB) has submitted 432+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in AnaptysBio's financial statements. The most recent filing was a Form 4 submitted on October 2, 2026.

Form 4
ANAPTYSBIO, INC Reports Ownership Change on Oct. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
AnaptysBio Files Current Report on Sep. 21, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
AnaptysBio Files Quarterly Report on May. 12, 2026

The 10-Q contains AnaptysBio's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

AnaptysBio SEC Filing History

Browse AnaptysBio's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
10/02/2026 4:47 PM
AnaptysBio (1370053) Issuer
RENTON HOLLINGS (1187333) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/21/2026 3:23 PM
AnaptysBio (1370053) Filer
Form 10-KT
09/21/2026 3:20 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/17/2026 3:05 PM
AnaptysBio (1370053) Issuer
Orwin John A (1477384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/14/2026 7:31 AM
AnaptysBio (1370053) Subject
Sirenia Capital Management LP (2115022) Filed by
Form SCHEDULE 13G/A
08/11/2026 3:05 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2026 4:12 PM
AnaptysBio (1370053) Issuer
Faga Daniel (1673528) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 4:13 PM
AnaptysBio (1370053) Issuer
Lizzul Paul F. (1711462) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/30/2026 3:05 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/13/2026 3:12 PM
AnaptysBio (1370053) Subject
Ware J. Anthony (1715429) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/30/2026 3:04 PM
AnaptysBio (1370053) Subject
Ware J. Anthony (1715429) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 3:15 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 3:05 PM
AnaptysBio (1370053) Filer
Form DEF 14A
06/26/2026 3:46 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/22/2026 3:05 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2026 3:29 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/17/2026 3:05 PM
AnaptysBio (1370053) Issuer
Orwin John A (1477384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2026 3:05 PM
AnaptysBio (1370053) Issuer
RENTON HOLLINGS (1187333) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2026 3:05 PM
AnaptysBio (1370053) Issuer
Schmid John P. (1478916) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2026 4:28 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/15/2026 4:47 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/11/2026 3:47 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/10/2026 3:38 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2026 4:08 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/08/2026 4:20 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2026 4:22 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2026 11:36 AM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2026 4:16 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/02/2026 3:37 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/01/2026 4:50 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/29/2026 3:15 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/28/2026 4:17 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2026 3:46 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/26/2026 3:17 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/19/2026 4:37 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2026 7:09 AM
AnaptysBio (1370053) Subject
Sirenia Capital Management LP (2115022) Filed by
Form SCHEDULE 13G
05/13/2026 4:48 PM
AnaptysBio (1370053) Issuer
Murphy Christopher M. (2005986) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/13/2026 4:48 PM
AnaptysBio (1370053) Issuer
Murphy Christopher M. (2005986) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2026 4:49 PM
AnaptysBio (1370053) Issuer
Hughes Owen (1575933) Reporting
Form 3
Initial statement of beneficial ownership of securities  
05/13/2026 4:50 PM
AnaptysBio (1370053) Issuer
Hughes Owen (1575933) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 3:17 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
The case for $20,000 gold before year end (Ad)

President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.tc pixel

Read the full gold report and see Eifrig's top pick now
05/12/2026 3:20 PM
AnaptysBio (1370053) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/11/2026 3:05 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2026 3:05 PM
AnaptysBio (1370053) Issuer
GRAY SUSANNAH (1833453) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 3:17 PM
AnaptysBio (1370053) Filer
Form 8-K/A
04/23/2026 5:07 PM
AnaptysBio (1370053) Issuer
Faga Daniel (1673528) Reporting
Form 4/A
04/22/2026 5:33 PM
AnaptysBio (1370053) Issuer
Faga Daniel (1673528) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 5:34 PM
AnaptysBio (1370053) Issuer
RENTON HOLLINGS (1187333) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 5:35 PM
AnaptysBio (1370053) Issuer
Schmid John P. (1478916) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 5:35 PM
AnaptysBio (1370053) Issuer
Orwin John A (1477384) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 3:05 PM
AnaptysBio (1370053) Reporting
First Tracks Biotherapeutics, Inc. (2091349) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:25 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/03/2026 3:00 PM
AnaptysBio (1370053) Issuer
GRAY SUSANNAH (1833453) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/01/2026 8:28 PM
AnaptysBio (1370053) Issuer
Schmid John P. (1478916) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2026 3:31 PM
AnaptysBio (1370053) Reporting
First Tracks Biotherapeutics, Inc. (2091349) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/27/2026 7:15 PM
AnaptysBio (1370053) Issuer
Faga Daniel (1673528) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 8:19 AM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/26/2026 2:43 PM
AnaptysBio (1370053) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
02/11/2026 3:36 PM
AnaptysBio (1370053) Subject
LOUMEAU ERIC J (1239648) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/11/2026 12:16 PM
AnaptysBio (1370053) Subject
MORGAN STANLEY (895421) Filed by
Form SCHEDULE 13G/A
01/16/2026 3:16 PM
AnaptysBio (1370053) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
01/16/2026 12:05 PM
AnaptysBio (1370053) Issuer
Marquet Magda (1631486) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/15/2026 3:06 PM
AnaptysBio (1370053) Subject
Marquet Magda (1631486) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 6:11 PM
AnaptysBio (1370053) Subject
Faga Daniel (1673528) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 6:12 PM
AnaptysBio (1370053) Issuer
Faga Daniel (1673528) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 6:12 PM
AnaptysBio (1370053) Subject
LOUMEAU ERIC J (1239648) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 6:13 PM
AnaptysBio (1370053) Issuer
LOUMEAU ERIC J (1239648) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 6:14 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 6:14 PM
AnaptysBio (1370053) Issuer
MULROY DENNIS (1276840) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 6:15 PM
AnaptysBio (1370053) Subject
Lizzul Paul F. (1711462) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 6:16 PM
AnaptysBio (1370053) Issuer
Lizzul Paul F. (1711462) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/09/2026 4:17 PM
AnaptysBio (1370053) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 3:05 PM
AnaptysBio (1370053) Issuer
Marquet Magda (1631486) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:06 PM
AnaptysBio (1370053) Issuer
Jain Rita (1707797) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:07 PM
AnaptysBio (1370053) Issuer
FENTON DENNIS M (1184627) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:08 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2026 3:08 PM
AnaptysBio (1370053) Issuer
MULROY DENNIS (1276840) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:09 PM
AnaptysBio (1370053) Subject
Faga Daniel (1673528) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2026 3:10 PM
AnaptysBio (1370053) Issuer
Faga Daniel (1673528) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:10 PM
AnaptysBio (1370053) Subject
Lizzul Paul F. (1711462) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2026 3:11 PM
AnaptysBio (1370053) Issuer
Lizzul Paul F. (1711462) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 3:12 PM
AnaptysBio (1370053) Subject
LOUMEAU ERIC J (1239648) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/08/2026 3:12 PM
AnaptysBio (1370053) Issuer
LOUMEAU ERIC J (1239648) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 3:06 PM
AnaptysBio (1370053) Subject
LOUMEAU ERIC J (1239648) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 8:02 PM
AnaptysBio (1370053) Subject
LOUMEAU ERIC J (1239648) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 8:03 PM
AnaptysBio (1370053) Issuer
LOUMEAU ERIC J (1239648) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 8:04 PM
AnaptysBio (1370053) Subject
Lizzul Paul F. (1711462) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 8:04 PM
AnaptysBio (1370053) Issuer
Lizzul Paul F. (1711462) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 8:05 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 8:05 PM
AnaptysBio (1370053) Issuer
MULROY DENNIS (1276840) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 8:07 PM
AnaptysBio (1370053) Subject
Faga Daniel (1673528) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
MILLIONAIRE MASTERCLASS INVITE: Altucher (Ad)

James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.tc pixel

Watch James Altucher's free masterclass before December 8th
01/06/2026 8:07 PM
AnaptysBio (1370053) Issuer
Faga Daniel (1673528) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:29 PM
AnaptysBio (1370053) Issuer
Schmid John P. (1478916) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:30 PM
AnaptysBio (1370053) Issuer
Ware J. Anthony (1715429) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:27 PM
AnaptysBio (1370053) Issuer
LOUMEAU ERIC J (1239648) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:28 PM
AnaptysBio (1370053) Issuer
MULROY DENNIS (1276840) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:28 PM
AnaptysBio (1370053) Issuer
Lizzul Paul F. (1711462) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:03 PM
AnaptysBio (1370053) Subject
Ware J. Anthony (1715429) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/22/2025 3:01 PM
AnaptysBio (1370053) Subject
MULROY DENNIS (1276840) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/22/2025 3:04 PM
AnaptysBio (1370053) Subject
Lizzul Paul F. (1711462) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

AnaptysBio SEC Filings - Frequently Asked Questions

AnaptysBio (ANAB) has submitted 432+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

AnaptysBio's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on AnaptysBio's financial statements page.

The most recent filing was a Form 4 submitted on October 2, 2026. This was an insider ownership change filed by 4 - ANAPTYSBIO, INC (0001370053) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:ANAB are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 10/2/2026. New filings are added as they're published.
From Our Partners